Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Short term Debt (2019 - 2025)

Opus Genetics has reported Short term Debt over the past 4 years, most recently at $21.3 million for Q3 2025.

  • Quarterly Short term Debt changed N/A to $21.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $21.3 million through Sep 2025, changed N/A year-over-year, with the annual reading at $2.7 million for FY2019, N/A changed from the prior year.
  • Short term Debt was $21.3 million for Q3 2025 at Opus Genetics, up from $11.8 million in the prior quarter.
  • Over five years, Short term Debt peaked at $21.3 million in Q3 2025 and troughed at $93000.0 in Q3 2023.
  • The 3-year median for Short term Debt is $11.8 million (2025), against an average of $9.2 million.